INZY Stock Overview
A clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Inozyme Pharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$5.11 |
52 Week High | US$7.80 |
52 Week Low | US$2.69 |
Beta | 1.52 |
11 Month Change | -9.88% |
3 Month Change | 11.82% |
1 Year Change | 3.44% |
33 Year Change | -67.35% |
5 Year Change | n/a |
Change since IPO | -70.87% |
Recent News & Updates
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?
Aug 03Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion
Jul 30Recent updates
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?
Aug 03Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion
Jul 30Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?
Apr 11Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward
Mar 08Inozyme Pharma GAAP EPS of -$0.38
Aug 15Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency
Jul 19Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?
Jul 12We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
Apr 06Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation
Dec 22Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth
Sep 08We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
May 22Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency
May 07We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely
Feb 06Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder
Jan 04Inozyme Pharma (INZY) Investor Presentation - Slideshow
Dec 03Inozyme Pharma EPS misses by $1.02
Nov 12Shareholder Returns
INZY | US Biotechs | US Market | |
---|---|---|---|
7D | 9.0% | 1.7% | 0.4% |
1Y | 3.4% | 14.8% | 25.3% |
Return vs Industry: INZY underperformed the US Biotechs industry which returned 15.1% over the past year.
Return vs Market: INZY underperformed the US Market which returned 24.9% over the past year.
Price Volatility
INZY volatility | |
---|---|
INZY Average Weekly Movement | 7.8% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: INZY has not had significant price volatility in the past 3 months.
Volatility Over Time: INZY's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 59 | Doug Treco | www.inozyme.com |
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company’s lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products.
Inozyme Pharma, Inc. Fundamentals Summary
INZY fundamental statistics | |
---|---|
Market cap | US$321.83m |
Earnings (TTM) | -US$88.56m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.6x
P/E RatioIs INZY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
INZY income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$88.56m |
Earnings | -US$88.56m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.41 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 48.0% |
How did INZY perform over the long term?
See historical performance and comparison